Serum visfatin is differentially regulated by insulin and free fatty acids in healthy men

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages

  Kowalska, Irina ^a   Karczewska Kupczewska, Monika ^a   Adamska, Agnieszka ^a   Nikolajuk, Agnieszka ^b   Otziomek, Elzbieta ^a   Straczkowski, Marek ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b INSTITUTE OF ANIMAL REPRODUCTION AND FOOD RESEARCH   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; INSULIN; INTERLEUKIN 6; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME REGULATION; ENZYME RELEASE; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; INSULIN SENSITIVITY; MALE; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADULT; FATTY ACIDS, NONESTERIFIED; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

EID: 84873615551     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2818     Document Type: Article

References (20)

1. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 2009;20:130-138.
2. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/human pre-B-colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91:295-299.
3. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentration in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006; 91:1578-1581.
4. Kowalska I, Stra{ogonek}czkowski M, Nikołajuk A, et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod. 2007;22:1824-1829.
5. Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis. 2011;21:245-253.
6. Friebe D, Neef M, Kratzsch J, et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT/pre-B colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 2011;54:1200-1211.
7. Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of adipocytokine visfatin is regulated by glucose and insulin. Diabetologia. 2006;49:1909-1914.
8. Bala M, Martin J, Kopp A, Hanses F, Buechler C, Schaffler A. In vivo suppression of visfatin by oral glucose uptake: evidence for a novel incretin-like effect by glucagon-like peptide 1 (GLP-1). J Clin Endocrinol Metab. 2011;96:2493-2501.
9. Hofso D, Uealnd T, Hager H, et al. Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. Eur J Endocrinol. 2009;161:451-458.
10. Karczewska-Kupczewska M, Kowalska I, Nikolajuk A, et al. Circulating brain-derived neurotrophic factor concentration is down-regulated by intralipid/heparin infusion or high-fat meal in young healthy male subjects. Diabetes Care. 2012;35:358-362.
11. Nikolajuk A, Kowalska I, Karczewska-Kupczewska M, et al. Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome. Diabetes. 2010;59:1026-1029.
12. Dandona P, Ghanim H, Bandyopadhyay A, et al. Insulin suppresses endotoxin-induced oxidative, nitrosative and inflammatory stress in humans. Diabetes Care. 2010;33:2416-2423.
13. Boden G, Jadali F, White J, et al. Effect of fat on insulin-stimulated carbohydrate metabolism in normal men. J Clin Invest. 1991;180: 960-966.
14. Boden G, Cheung P, Stein TP, Kesge K, Mozzoli M. FFA cause hepatic insulin resistance by inhibiting insulin secretion of glycogenolysis. Am J Physiol Endocrinol Metab. 2002;283:E12-E19.
15. Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre-B-cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006;91:3165-3170.
16. Haider DG, Mittermayer F, Schaller G, et al. Free fatty acids normalize a rosiglitazone-induced visfatin release. Am J Physiol Endocrinol Metab. 2006;291:E885-E890.
17. Ciardi C, Tatarczyk T, Tschoner A, et al. Effect of postprandial lipemia on plasma concentrations of A-FABP, RBP-4 and visfatin. Nutr Metab Cardiovasc Dis. 2010;20:662-668.
18. Ingelsson E, Larson MG, Fox CS, et al. Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care. 2007;30:1278-1280.
19. Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab. 2007;92:4783-4791.
20. López-Bermejo A, Chico-Julià B, Fernà ndez-Balsells M, et al. Serum visfatin increases with progressive β-cell deterioration. Diabetes. 2006;2871-2875.